Clemow D, Radawski C, Milata J, Alaka K, Gibble TH, Schaum A, Ezennia O, Martinez N, Szaloki T, Ito Y, Rodriguez D, and Kirk K
Background: There is a need to better understand ulcerative colitis (UC) patient and healthcare provider (HCP) treatment satisfaction, acceptability, and preferences., Methods: Two international, cross-sectional, web-based surveys were conducted among participants of a phase 3 mirikizumab study (NCT03519945). The questions captured moderate-to-severe UC patients' experience, HCPs' perception of patients' experience, and HCPs' own experience with mirikizumab administration through intravenous (IV) infusions and subcutaneous (SC) injections., Results: Respondents included 93 patients and 42 HCPs from 11 countries. The majority of patients had UC >4 years (74.2%), were bionaive (68%), in remission at the time of the survey (63%). HCPs were primarily from the United States (57%), generally nurses (41%) or gastroenterologists (26%) with ≥6 years of experience in treating UC (57%). Most patients were "very satisfied/satisfied" (IV, 83%; SC, 91%), "completely/somewhat" accepting of mirikizumab administration (IV, 87%; SC, 97%), and agreed that improvement to their UC outweighed any administration dissatisfaction (90%). HCPs' perspectives of patients' experiences were higher: "very satisfied/satisfied" (IV, 93%; SC, 100%); "completely/somewhat" accepting (IV, 90%; SC, 98%). HCPs themselves were "very satisfied/satisfied" (IV, 81%; SC, 95%); gastroenterologists were "very satisfied" (IV, 82%; SC, 82%) more than nurses (IV, 29%; SC, 65%) who were generally at least "satisfied" (IV, 53%; SC, 35%). Two SC and monthly SC injections were "completely acceptable" by the patients (76% and 85%) and per HCPs' perceptions of patients' preferences (69% and 100%)., Conclusions: Both patients and HCPs were satisfied with and accepted mirikizumab IV induction followed by monthly maintenance SC injections. UC improvement outweighed any administration dissatisfaction., Competing Interests: David Clemow, Christine Radawski, Joe Milata, Karla Alaka, Theresa Hunter Gibble, Adam Schaum, and Obi Ezennia are employees of Eli Lilly at the time the study was conducted and the manuscript developed. Danielle Rodriguez and Katherine Kirk are employees of Evidera, which was contracted by Eli Lilly for work relating to this study. Tibor Szaloki is an employee of Javorszky Hospital and was contracted by Eli Lilly to assist as an external collaborator for this study. Nicholas Martinez is an employee of Gastroenterology Research of America and was contracted by Eli Lilly to assist as an external collaborator for this study. Yuka Ito is an employee of NHO Mito Medical Center and was contracted by Eli Lilly to assist as an external collaborator for this study. Medical writing support was provided by Athanasia Benekou, Principal Medical Writer, from Evidera’s Medical Writing and Healthcare Communications, and funded by Eli Lilly., (© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.)